Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• The combination of antibodies targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) shows promise for improving cancer treatment efficacy.
• Developing novel therapeutic agents that simultaneously modulate these immune checkpoints is a key area of research.

Purpose of the Study:

• To develop and characterize Z15-0, a bispecific nanobody targeting both PD-1 and CTLA-4 pathways.
• To optimize the mRNA sequence encoding Z15-0 (Z15-0-2) for enhanced expression and evaluate its antitumor activity.

Main Methods:

• mRNA sequence design and optimization for the bispecific nanobody Z15-0.
• In vitro experiments to assess nanobody expression levels.
• In vivo studies using tumor-bearing mice to evaluate antitumor efficacy.

Main Results:

• The optimized Z15-0-2 mRNA sequence significantly increased the expression of the bispecific nanobody.
• Administration of Z15-0-2 mRNA resulted in greater inhibition of tumor growth in mice compared to control groups.
• Demonstrated successful development of a bispecific nanobody with enhanced mRNA expression.

Conclusions:

• A novel bispecific nanobody, Z15-0, targeting PD-1 and CTLA-4 has been successfully developed.
• mRNA re-engineering of Z15-0 to Z15-0-2 significantly boosted its expression, leading to enhanced antitumor efficacy.
• This work represents a new drug development paradigm for bispecific immunotherapies.